ACE-031 (ramatercept) added roughly 3 percent lean body mass after a single subcutaneous dose in healthy volunteers with no exercise involved, and its phase 2 trial in Duchenne muscular dystrophy was halted in 2013 after participants developed nosebleeds, gum bleeding and visible dilated blood vessels. Understanding ACE-031 (ramatercept) means holding those two facts together, because the second one is a direct consequence of the mechanism that produced the first.
It is not a peptide. Structurally it is a two part biologic: the outward facing binding portion of activin receptor type IIB, stitched onto a human IgG1 antibody tail. That antibody tail is what gives it a half life measured in weeks rather than hours.
How the Mechanism Works
Myostatin is a negative regulator of muscle growth. It binds the activin type II receptor on muscle cells and signals them to limit hypertrophy. Blocking that signal removes a brake.
ACE-031 does not block the receptor on the cell. It is a soluble copy of the receptor's binding domain, circulating in the bloodstream, capturing ligands before they reach the real receptors. That is what makes it a decoy or ligand trap.
The problem is that ActRIIB is not a myostatin specific receptor. It binds a family of TGF-beta superfamily ligands, and a soluble copy of its binding domain traps all of them:
- Myostatin, the intended target
- Activin A and activin B
- GDF-11, involved in development and possibly ageing biology
- BMP-9 and BMP-10, which maintain vascular endothelium
That last pair is the one that ended the programme.
ACE-031 (Ramatercept) Dosage Used in Trials
These doses were administered in supervised clinical trials. ACE-031 is not approved anywhere and the programme was discontinued.
| Study context | Dosing | Result |
|---|---|---|
| Phase 1, healthy postmenopausal women | Single subcutaneous dose | Around 3 percent lean body mass increase and around 5 percent thigh muscle volume increase at day 29, without exercise |
| Phase 2, Duchenne muscular dystrophy | Repeated subcutaneous dosing every two to four weeks | Halted before completion |
| Half life | Approximately 10 to 15 days | The Fc fusion is what extends it |
The single dose phase 1 result is what drives the continuing interest. Adding several percent of lean body mass in a month, in untrained older women, without any training stimulus, is not a result other muscle interventions produce.
What Went Wrong
Participants in the Duchenne trial developed epistaxis, bleeding from the gums, and telangiectasias, meaning small dilated vessels visible at the skin surface. Acceleron halted the trial in 2013.
BMP-9 and BMP-10 are the likely explanation. Both signal through ActRIIB and both are involved in maintaining vascular endothelial integrity and regulating angiogenesis. Removing them from circulation alongside myostatin disrupted the vasculature.
This matters for how the compound should be understood. The bleeding was not an idiosyncratic reaction in a few patients or an impurity problem. It was the predictable consequence of a deliberately broad mechanism, and it appeared in a monitored trial population with clinical oversight.
Other Reported Effects
Beyond the vascular signal, reported effects across the trials included:
- Injection site reactions
- Headache
- Fatigue
- Changes in gonadal hormone levels, consistent with activin and inhibin pathway involvement
- Nasal congestion
Longer term effects were never characterised, because the programme did not run long enough.
The hormonal point is worth expanding. Activin and inhibin signalling is involved in reproductive endocrine regulation, and a compound that traps activin broadly is intervening in that system whether or not that was the intention. Changes in gonadal hormones were observed in the trials, and what sustained interference would do over months is not known.
There is also a general principle about ligand traps that applies here. Because the molecule works by removing signalling proteins from circulation rather than by blocking a receptor on a specific tissue, its effects are systemic by construction. There is no way to target the muscle and spare the vasculature, because the intervention happens in the bloodstream rather than at the tissue.
Why It Persists on Research Chemical Markets
ACE-031 appears for sale as a research compound, and the appeal is obvious: a drug with demonstrated lean mass effects that no regulator will ever approve.
Several things make that a poor proposition:
The safety signal was found in a monitored population. Trial participants had clinical oversight and their adverse events were caught. Someone injecting a research vial at home has no monitoring and no comparison group.
The half life is long. Two weeks of persistent activity means an adverse effect cannot be reversed by stopping. There is no rapid off switch.
Product identity is unverifiable in practice. ACE-031 is a fusion protein, not a short peptide. Confirming that a vial contains correctly folded, correctly glycosylated fusion protein is beyond what an HPLC purity number establishes, and most suppliers of this compound are not producing biologics to any recognisable standard.
The vascular effect is the mechanism, not a side effect. Reducing the dose does not remove the BMP trapping, it reduces it proportionally along with everything else.
There is no way to monitor for it early. The visible signs, nosebleeds and telangiectasias, are late indicators of a vascular process that has already been underway. There is no routine test that would flag it before that point, which means a self directed user finds out at the same time everyone else would.
It is also prohibited in competitive sport under anti-doping rules, alongside every other myostatin pathway agent, which applies regardless of approval status.
For a comparison with the more selective approach that succeeded where this one failed, see ACE-031 vs apitegromab. For evidence based alternatives, peptides for muscle growth covers what the field actually supports.
FAQ
What is ACE-031 also called?
Ramatercept. Acceleron Pharma developed it in partnership with Shire, and the technical shorthand for it is a soluble ActRIIB-Fc construct.
How much muscle does ACE-031 add?
One injection, given to healthy postmenopausal volunteers during phase 1 testing, raised lean body mass by roughly 3 percent and thigh muscle volume by around 5 percent within 29 days, with no training involved. Longer term effects in trained individuals were never studied.
Why did ACE-031 trials stop?
The phase 2 Duchenne trial was halted in 2013 after participants developed nosebleeds, gum bleeding and telangiectasias. These are attributed to the drug trapping BMP-9 and BMP-10, which maintain vascular integrity, alongside its intended target.
Is ACE-031 safe at lower doses?
Nobody knows, and the mechanism gives little reason for optimism. Lowering the dose reduces BMP trapping proportionally along with myostatin trapping, so the ratio of benefit to vascular risk does not obviously improve. No study has tested this.
Is there a safer version of ACE-031?
Selective anti-myostatin antibodies such as apitegromab were developed precisely to avoid this problem, and they produce smaller muscle effects as a result. None is approved for use in healthy adults.
